Oblimersen Sodium
drug drugOn this page
Also known as AugmerosenD-G3139G-3139G3139GenasenseOblimersen
Summary
Oblimersen Sodium (CHEMBL2109229) is a phase-3 clinical-stage oligonucleotide; indicated across 29 conditions including cutaneous melanoma and leukemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Oligonucleotide
- Indications: 29 conditions
- Clinical trials: 39
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109229 |
| Name | Oblimersen Sodium |
| Type | Oligonucleotide |
| Max phase | 3 |
Also known as: Augmerosen, D-G3139, G-3139, G3139, Genasense, Oblimersen, Oblimersen sodium, OBLIMERSEN SODIUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
25 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| cutaneous melanoma | 3 | MONDO:0005012 | EFO:0000389 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| melanoma | 3 | MONDO:0005105 | EFO:0000756 |
| plasma cell myeloma | 3 | MONDO:0009693 | EFO:0001378 |
| cutaneous neuroendocrine carcinoma | 2 | MONDO:0019210 | EFO:1001471 |
| chronic myeloid leukemia | 2 | MONDO:0011996 | EFO:0000339 |
| diffuse large B-cell lymphoma | 2 | MONDO:0018905 | EFO:0000403 |
| renal cell carcinoma | 2 | MONDO:0005086 | EFO:0000681 |
| small cell lung carcinoma | 2 | MONDO:0008433 | EFO:0000702 |
| lung neoplasm | 2 | MONDO:0021117 | MONDO:0008903 |
| follicular lymphoma | 2 | MONDO:0018906 | MONDO:0018906 |
| gastrointestinal stromal tumor | 2 | MONDO:0011719 | MONDO:0011719 |
| plasma cell neoplasm | 2 | MONDO:0004959 | EFO:0000200 |
| B-cell chronic lymphocytic leukemia | 1 | MONDO:0004948 | EFO:0000095 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| male breast carcinoma | 1 | MONDO:0005628 | EFO:0006861 |
| mantle cell lymphoma | 1 | MONDO:0018876 | EFO:1001469 |
| head and neck cancer | 1 | MONDO:0005627 | EFO:0006859 |
| Waldenstrom macroglobulinemia | 1 | MONDO:0100280 | EFO:0009441 |
| kidney disorder | 1 | MONDO:0005240 | EFO:0003086 |
| kidney cancer | 1 | MONDO:0002367 | MONDO:0002367 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
| colorectal neoplasm | 1 | MONDO:0005335 | MONDO:0005575 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 39.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 13 |
| PHASE1/PHASE2 | 9 |
| PHASE1 | 9 |
| PHASE3 | 5 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00016263 | PHASE3 | COMPLETED | Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma |
| NCT00017602 | PHASE3 | COMPLETED | Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| NCT00024440 | PHASE3 | COMPLETED | Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| NCT00030641 | PHASE2/PHASE3 | UNKNOWN | Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer |
| NCT00085124 | PHASE3 | COMPLETED | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia |
| NCT00517218 | PHASE3 | WITHDRAWN | This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) |
| NCT00003103 | PHASE1/PHASE2 | COMPLETED | Chemotherapy in Treating Patients With Solid Tumors |
| NCT00004870 | PHASE1/PHASE2 | COMPLETED | Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
| NCT00005032 | PHASE1/PHASE2 | COMPLETED | Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer |
| NCT00017589 | PHASE2 | COMPLETED | Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia |
| NCT00021749 | PHASE1/PHASE2 | COMPLETED | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia |
| NCT00042978 | PHASE2 | COMPLETED | Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer |
| NCT00047229 | PHASE2 | COMPLETED | Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) |
| NCT00049192 | PHASE2 | COMPLETED | Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
| NCT00049374 | PHASE2 | COMPLETED | Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| NCT00054639 | PHASE2 | COMPLETED | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
| NCT00055822 | PHASE1/PHASE2 | COMPLETED | Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer |
| NCT00059813 | PHASE2 | COMPLETED | Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer |
| NCT00062244 | PHASE1/PHASE2 | COMPLETED | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom’s Macroglobulinemia |
| NCT00063934 | PHASE1/PHASE2 | TERMINATED | Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer |
| NCT00064259 | PHASE1/PHASE2 | TERMINATED | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer |
| NCT00079131 | PHASE2 | COMPLETED | Oblimersen in Treating Patients With Merkel Cell Carcinoma |
| NCT00080847 | PHASE2 | TERMINATED | S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin’s Lymphoma |
| NCT00085228 | PHASE2 | COMPLETED | Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate |
| NCT00086944 | PHASE1/PHASE2 | COMPLETED | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma |
| NCT00091078 | PHASE2 | TERMINATED | Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery |
| NCT00301795 | PHASE2 | TERMINATED | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin’s Lymphoma |
| NCT01200342 | PHASE2 | TERMINATED | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma |
| NCT00004862 | PHASE1 | COMPLETED | Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
| NCT00017251 | PHASE1 | COMPLETED | Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer |
| NCT00039117 | PHASE1 | COMPLETED | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia |
| NCT00039481 | PHASE1 | COMPLETED | Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors |
| NCT00054548 | PHASE1 | COMPLETED | Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors |
| NCT00060112 | PHASE1 | TERMINATED | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma |
| NCT00070083 | PHASE1 | COMPLETED | Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma |
| NCT00543231 | PHASE1 | COMPLETED | A Phase I Study of G3139 Subcutaneous in Solid Tumors |
| NCT00636545 | PHASE1 | COMPLETED | Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors |
| NCT00736450 | EARLY_PHASE1 | TERMINATED | Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma |
| NCT00070343 | Not specified | UNKNOWN | Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: cutaneous melanoma, leukemia, melanoma, plasma cell myeloma, cutaneous neuroendocrine carcinoma, chronic myeloid leukemia, diffuse large B-cell lymphoma, renal cell carcinoma, small cell lung carcinoma, lung neoplasm, follicular lymphoma, gastrointestinal stromal tumor, plasma cell neoplasm